Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01930591 | Ticagrelor for PCI Post Thrombolysis | PHASE3 | COMPLETED | 140 | — | — | May 1, 2014 | Nov 1, 2016 | Nov 22, 2016 | 5 | Canada |
Therapeutic platelet inhibition as determined by VerifyNow assay (PRU value \<208) at 4±1 hours post PCI
| Arm | Type | Description |
|---|---|---|
| Clopidogrel arm | ACTIVE_COMPARATOR | Clopidogrel 300 mg before PCI followed by 75 mg po OD |
| Ticagrelor arm | EXPERIMENTAL | Ticagrelor 180 mg before PCI followed by 90 mg po BID |
| Name | Type | Description |
|---|---|---|
| Ticagrelor | DRUG | 180 mg bolus followed by 90 mg BID |
| Clopidogrel | DRUG | 300 mg bolus followed by 75 mg OD |
Inclusion Criteria: 1. Age 18 years and over. 2. Planned PCI between 4-24 hours after administration of fibrinolytic therapy for STEMI. 3. Treatment with aspirin and clopidogrel as an adjunct to fibrinolytic therapy. 4. Informed written consent. Exclusion Criteria: 1. Atrial fibrillation or need ...